Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret
Fierce Pharma
MARCH 10, 2023
Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret kdunleavy Fri, 03/10/2023 - 10:22
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Fierce Pharma
MARCH 10, 2023
Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret kdunleavy Fri, 03/10/2023 - 10:22
Fierce Pharma
OCTOBER 2, 2023
Even as Biogen weighs strategic options for its biosimilars unit, the group is celebrating an industry first. | The exact launch timing of the biosimilar remains unclear, but Roche said it expects competition to kick off in the second half of 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JULY 11, 2023
With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely. With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely.
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
European Pharmaceutical Review
NOVEMBER 3, 2022
Results from CPhI’s 2022 Pharma Index survey , announced at this year’s CPhI Frankfurt, showed pharma confidence in growth , innovation and manufacturing quality has reached record highs, promising positive prospects for the industry in 2023 and beyond. Competitiveness. Key countries. Finished Dosage. Growth potential.
World of DTC Marketing
MARCH 17, 2021
The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the whole industry is winning praise for co-operation” However, the bump in reputation will be short-lived because companies need to earn the public’s trust every day, and pharma is already damaging their perception with people.
European Pharmaceutical Review
OCTOBER 10, 2023
The current Voluntary Scheme is due to end in December 2023. Jackie Williams, General Manager of Astellas Pharma Ltd emphasised that if implemented, the proposals would place “a negative impact on new product launches, despite any initial exemption in the first three years.”
pharmaphorum
JANUARY 9, 2023
This Nine for 2023 three-part series will argue that, this year, the future-facing Janus prediction of unprecedented and transformative change is true. However, the pandemic is only one of the often deep-rooted forces that will come together in 2023 to exert transformative pressure on healthcare.
European Pharmaceutical Review
APRIL 28, 2023
The European Commission ’s (EC’s) reform of the EU pharmaceutical legislation published on 26 April 2023, adopted a proposal for a new Directive and a new Regulation. To mitigate this, he strongly recommended “a comprehensive competitiveness check is conducted on the impact of the revised pharmaceutical legislation.”
PM360
SEPTEMBER 21, 2023
Jeff Casberg, MS, RPh, Senior Vice President of Clinical Pharmacy at IPD Analytics, a managed care and pharmaceutical consultancy, highlighted a wide range of 2023 key events that will affect managed care professionals by the end of the year. This product is expected to have three generic launches in 2023.
Star OUTiCO
NOVEMBER 30, 2022
January is one of the busiest recruiting times, so starting your hunt this month could mean lower competition and possibly improve your odds of securing your dream job. Reassess ahead of 2023. Some larger pharma clients are really going above and beyond to try and dangle that golden carrot Sarah Whitby, Pharma Outsourcing Lead.
European Pharmaceutical Review
MARCH 7, 2023
The Pistoia Alliance has launched its Pharma Innovation Council. The Council will explore common challenges develop ideas for new pre-competitive projects aligned with the Alliance’s strategic themes, including Emerging Sciences and Technology and Improving the Efficiency and Effectiveness of R&D.
European Pharmaceutical Review
SEPTEMBER 13, 2023
As small and medium-sized enterprises (SMEs) often face unfair competition when doing business in Europe, through the (SME) Relief Communication, the European Commission (EC) has proposed new measures to provide short-term relief, boost long-term competitiveness, and improve equality in the business environment across the Single Market in Europe.
pharmaphorum
DECEMBER 28, 2022
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma industry.
Pharmaceutical Technology
JANUARY 30, 2023
on National Health Service (NHS) sales of branded medicines in 2023, almost double that of the previous year, has sent shock waves through the pharma industry. During 2019–21, when sales being close to predicted levels resulted in single-digit payback rates, the scheme was relatively popular with the pharma sector. billion ($4.1
pharmaphorum
JANUARY 5, 2023
As Chancellor of the Exchequer Jeremy Hunt said: “I want British firms to lead the world in turning fantastic science into new products and services – and we need to make sure government is doing everything we can to encourage innovation and competition.”. The post It’s time for more tech and biotech innovation in 2023 appeared first on.
Impetus Digital
AUGUST 2, 2024
Looking back at 2023 , AI for drug discovery saw both wins and losses. Supply Chain Management Due to geopolitical and climate-related challenges , Pharma supply chain disruptions are becoming increasingly common and complex. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%.
Pharma Marketing Network
APRIL 5, 2023
Attending the Reuters Pharma Marketing 2023 event on March 28-29 was a fascinating experience as the pharma marketing industry continues to return to in-person events. We also saw the addition of a track focused on Cell and Gene Therapy, as Pharma ventures into the commercialization of therapeutics.
pharmaphorum
JANUARY 16, 2023
The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023. Innovation will power the market.
Pharma Marketing Network
DECEMBER 17, 2021
The pharma industry has been slower to embrace digital technologies than other less-regulated sectors but the COVID-19 pandemic has greatly changed this long-standing mindset. In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. HCP Engagement and Pharma Salesforces.
PM360
APRIL 7, 2023
However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. pharma sales in 2020) and the size of 340B discounts (25-50%), companies may see significantly reduced revenues for important products.
pharmaphorum
DECEMBER 15, 2022
A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. “The industry now regards the current approach, due to end in 2023, as broken.” VPAS tax on top. . VPAS tax on top. .”
pharmaphorum
SEPTEMBER 15, 2022
The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company – now confirmed to be Novartis – as part of an investigation into a “possible unlawful use of a patent to reduce competitive pressure.”
Pharmaceutical Technology
MAY 11, 2023
The global pharma industry experienced a 9% drop in social media posts on internet of things in Q1 2023 compared with the previous quarter, with the highest share accounted for U.S. Of the 50 leading companies in the pharma industry, U.S. Buy the report here.
European Pharmaceutical Review
NOVEMBER 30, 2023
Cell and gene therapy industry in 2023 According to data from the GMP Manufacturing Survey, in the past year: “There is an increase in the number of manufacturing organisations and the number of licensed facilities has remained stable. The 2023 data found that the split for bioprocessing roles was 57 percent.
pharmaphorum
SEPTEMBER 5, 2022
The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”
pharmaphorum
JULY 21, 2022
The appointment might raise some eyebrows given Roche’s need to drive pharma sales as it copes with the loss of patent protection on an earlier generation of antibody-based therapies – now being hit by biosimilar competition – but Schwan is confident Schinecker is the right man to lead the company forward. billion ($33.2
Clarivate
MAY 8, 2024
A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. As a result, 2023 saw an upsurge in merger and acquisition (M&A) and deal activity. According to BioWorld, M&A values in 2023 jumped 80% over 2022, and deal values reached BioWorld’s highest level ever recorded.
Pharma Marketing Network
MARCH 23, 2023
As cookies become obsolete, pharma marketers will need to find new ways to reach and engage with consumers. For example, pharma marketers can use email marketing to reach consumers with relevant health and wellness information, or use SMS marketing to send appointment reminders or refill notifications. References: 1. ” Hubspot.
Clarivate
DECEMBER 19, 2022
For 2023 Medicare Advantage open enrollment, the United States’ largest retailer will begin a 10-year partnership with the nation’s largest insurer. The partnership dovetails with Walmart Health’s plans for 15 new Florida clinics across the Jacksonville, Orlando and Tampa markets by the end of 2023. MA national enrollment.
PharmaKinnex
SEPTEMBER 28, 2022
How PharmaKinnex Helps You Plan For A Better 2023 September 27, 2022. Everyone knows that over the next few weeks and months, businesses in the pharma marketing industry will meet to discuss next year’s budget. Keep reading to find out more about how our pharma marketing services can help make 2023 your best year yet.
Pharmaceutical Technology
MAY 16, 2023
More than half of the top 20 global biopharmaceutical companies saw a fall in market capitalisation over Q1 2023. trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This resulted in a 3.4% decline in total aggregate market capitalisation from $3.61 trillion in Q4 2022 to $3.49
European Pharmaceutical Review
MAY 13, 2024
Notably, 47 percent of respondents from the pharma and healthcare sectors considered that financial performance was “the main task of procurement”. Sustainability of the future pharma supply chain “Companies are now receiving uniform rules for the entire EU, which is particularly advantageous for the healthcare industry.
PM360
OCTOBER 13, 2023
For the next 12 to 24 months, the media landscape is set to drastically change and pharma marketers can’t miss this hidden opportunity. billion in 2023 from these fees. Threads on the other hand is the spitting image of brand safety—if pharma developed an industry-centric platform, this would be it. Will streaming evolve?
Eversana Intouch
JANUARY 19, 2023
Success in 2023 will mean addressing each of those five issues meaningfully – understanding them fully and giving them real action, not just lip service. – is changing, and has big implications for the competitive marketplace. Pharma marketers in 2023 need to: Look for blind spots. or technology, too?
Medico Reach
FEBRUARY 8, 2023
The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. Are you intrigued to know what technologies will rule the pharma market and how they can benefit your business in 2023? from 2022 to 2030, the pharma industry will reach USD 9,241.34 billion during 2020-2024.
Clarivate
JANUARY 23, 2024
The just-published 2023 Factbook indicates an industry that is becoming more nimble and efficient in its R&D over the long haul. Figure 1: Number of NME launches from 2013 to 2022 Analyses from the 2023 R&D Factbook also indicate that the number of late phase terminations has consistently declined in recent years.
Healthcare Success
NOVEMBER 7, 2022
They’re researching key trends that will attract new high-intent audiences, increase engagement, drive revenue, and reinforce patient loyalty in 2023. In this article, you’ll learn: 4 Advertising Planning Strategies for 2023 6 Marketing Strategies That Outpace Market Disruption. 4 Advertising Planning Strategies for 2023.
Clarivate
MAY 31, 2023
A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.
PM360
DECEMBER 20, 2023
With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.
pharmaphorum
SEPTEMBER 7, 2022
Gilead Sciences’ Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute lymphoblastic leukaemia (ALL) in Europe, free of direct competition from arch-rival Novartis. However, results from that are not due until 2023.
eMediWrite
AUGUST 30, 2023
Pharma MSMEs might not have the negotiation leverage or other options necessary to properly handle late payments. Challenges posed by payments that are late for pharma MSMEs For pharma MSMEs, late payments present formidable obstacles. The solution to the issue of delayed payments is collaboration.
Pharmaceutical Technology
DECEMBER 15, 2022
It also stresses that some pharma manufacturers are at risk of having gas rationed or being unable to continue manufacturing due to high prices. Once a drug’s patent expires, numerous pharma companies offer generic versions, which can then reduce drug pricing by as much as 80-90%, leading to small profit margins for generics makers.
Pharmaceutical Technology
FEBRUARY 8, 2023
trillion over the past year, according to GlobalData’s Pharma Intelligence Center Companies Database. billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. for 2022 according to GlobalData’s Drugs Database Pharma Intelligence Center analyst consensus. trillion to $3.61 and 31.6%, respectively.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content